fbpx

Lundbeckfonden Ventures

An evergreen international life science investor

Lundbeckfonden Ventures is an evergreen venture fund investing internationally in life science companies. Our focus is primarily projects and companies with development candidates close to or in clinical development. We are particularly interested in speciality pharma product opportunities and in technology platforms that have demonstrated their value in generating development candidates.

About us

Since 2009, we have invested in 28 companies in USA and Europe and have an active portfolio of around 20 companies representing a broad spectrum of therapeutic fields. Annually we invest 350 to 400 million Danish kroner.

We work internationally and as lead investor when investing in Europe. We are determined to add value to our investments and will involve ourselves actively in our portfolio companies and work in close collaboration with their management and boards.

Investment opportunities

We are seeking experienced and capable management teams that are committed to resolving the sometimes difficult challenges involved in development of drugs aimed at unmet medical needs. A well-defined plan is crucial as is strong and enforceable patent protection and a sound understanding of the relevant markets and their regulatory frameworks.

The starting point for us is a non-confidential presentation or summary of the project or company. If it falls within our strategic focus area, we will be prepared to enter into a confidentiality agreement and evaluate confidential information. Each investment is potentially a long-term commitment and therefore it is important for us to meet the team and get to know you during our evaluation. Consequently, the next step will be to arrange a meeting where we can discuss data, plans and investment proposals. Continued interest will lead to a thorough due diligence exercise before final deal negotiation.

You can send non-confidential information to: ventures@lundbeckfonden.com

Lundbeckfonden Ventures

News

scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
16. July 2019
Acacia Pharma Group PLC – Editorial on Positive Data for BARHEMSYS® Treatment of Post-Operative Nausea & Vomiting (PONV) Published in Anesthesia & Analgesia
12. July 2019
Acacia Pharma Group PLC – Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019
8. July 2019